Potential for immunotherapy: PEM as a target antigen
In looking for novel therapies for the effective treatment of ovarian cancer, particularly as an adjuvant to surgery, immunotherapy is an option which is ready to be explored. Two reasons why this option may now be a realistic one are that potential target antigens are being identified and considerable advances have been made in understanding the underlying mechanisms involved in tumour rejection and in antigen presentation and recognition by the various components of the immune system. The possibility of extending immunotherapy to prevention (at least for prevention of recurrence of the disease) is also a real one since active specific immunotherapy (ASI) appears to be unaccompanied by obvious serious side effects.
KeywordsOvarian Cancer Ovarian Cancer Patient Ovarian Cancer Cell Line Tumour Rejection MUC1 Gene
Unable to display preview. Download preview PDF.
- 4.Lamb, P. and Crawford, L. (1986) Characterization of the human p53 gene. Cancer Res., 6, 1379–85.Google Scholar
- 8.Linsley, P.S., Brady, W., Grosmaire, L. et al. (1992) Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation, J.Exp. Med., 173, 721–30.Google Scholar
- 19.Gunn, J.R., Byrd, J., Hicks, J. et al. (1989) Molecular cloning of human intestinal mucin cDNAs. J. Biol Chem., 264, 6480–7.Google Scholar
- 26.Hanish, F.G., Uhlenbruck, G., Peter-Katalinic, J. et al. (1989) Structure of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyl-lactosamine backbones with Galiβ(l-4) GlcNAciβ(l-6) repeating units. J. Biol Chem., 265, 872–83.Google Scholar
- 37.Ding, L., Lalani, E.N., Reddish, M. et al. (1993) Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUCl mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUCl gene. J. Cancer Immunol Immunother., 36, 9–17.CrossRefGoogle Scholar
- 41.Aldovini, A. and Young, R.A. (1991) Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature, 35, 1479–82.Google Scholar
- 42.Dranoff, G., Jaffee, E., Lazenby, A. et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte- macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA, 90, 3539–43.PubMedCrossRefGoogle Scholar